CS-8958 - A Phase I, Double-Blind, Placebo Controlled, Ascending Single Inhaled Dose, Safety, Tolerability and Pharmacokinetic Study in Elderly Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2016
At a glance
- Drugs Laninamivir (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Biota Holdings
- 16 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jan 2009 Planned number of patients changed from 24 to 38 as reported by ClinicalTrials.gov.
- 12 Jan 2009 Planned end date changed from 1 Sep 2008 to 1 Jun 2009 as reported by ClinicalTrials.gov.